Cholesterol 25-Hydroxylase Enhances Myeloid-Derived Suppressor Cell (MDSC) Immunosuppression via the Stimulator of Interferon Genes (STING)-Tank-Binding Kinase 1 (TBK1)-Receptor-Interacting Protein Kinase 3 (RIPK3) Pathway in Colorectal Cancer

Abstract

Myeloid-derived suppressor cells (MDSCs) represent a significant immunosuppressive population within the tumor microenvironment of colorectal cancer (CRC). Their activity has been strongly associated with the reprogramming of cholesterol metabolism, although the underlying mechanisms remain unclear. To investigate this, we generated myeloid-specific cholesterol 25-hydroxylase (CH25H) knockdown mice and differentiated bone marrow cells from wild-type (WT) or Ch25h^f/f Lyz2^Cre mice into MDSCs, subsequently treating them with 25-hydroxycholesterol (25HC). Immune function was evaluated using flow cytometry, Western blotting, and real-time polymerase chain reaction (PCR). Our findings indicated that CH25H and its metabolite 25HC were significantly upregulated in CRC-associated MDSCs. The loss of CH25H impaired their immunosuppressive capacity by reducing arginase-1 (ARG1) expression, an effect that was restored by 25HC supplementation. Mechanistically, 25HC suppressed the activation of the cyclic guanosine monophosphate–adenosine monophosphate synthase–stimulator of interferon genes (cGAS–STING) pathway and the downstream tank-binding kinase 1 (TBK1). TBK1 formed a complex with receptor-interacting protein kinase 3 (RIPK3), thereby repressing ARG1 expression through phosphorylation-dependent signaling. Collectively, these findings reveal a previously unrecognized CH25H–25HC–STING axis in MDSC-mediated immune regulation and suggest that targeting cholesterol metabolism may provide a promising therapeutic strategy for CRC immunotherapy.

Keywords

cholesterol metabolism / cholesterol 25-hydroxylase / colorectal cancer / myeloid-derived suppressor cells / stimulator of interferon genes / tumor immunosuppression / 25-hydroxycholesterol

References

[1] B. H. O'Neil, J. M. Wallmark, D. Lorente, et al., “Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients With Advanced Colorectal Carcinoma,” PLoS ONE 12, no. 12 (2017): e0189848.

[2] H. Zhao, L. Wu, G. Yan, et al., “Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 263.

[3] I. Sieminska and J. Baran, “Myeloid-Derived Suppressor Cells in Colorectal Cancer,” Frontiers in Immunology 11 (2020): 1526.

[4] S. He, L. Zheng, and C. Qi, “Myeloid-Derived Suppressor Cells (MDSCs) in the Tumor Microenvironment and Their Targeting in Cancer Therapy,” Molecular Cancer 24, no. 1 (2025): 5.

[5] D. I. Gabrilovich, “Myeloid-Derived Suppressor Cells,” Cancer Immunology Research 5, no. 1 (2017): 3-8.

[6] F. Veglia, E. Sanseviero, and D. I. Gabrilovich, “Myeloid-Derived Suppressor Cells in the Era of Increasing Myeloid Cell Diversity,” Nature Reviews Immunology 21, no. 8 (2021): 485-498.

[7] L. van Vlerken-Ysla, Y. Y. Tyurina, V. E. Kagan, and D. I. Gabrilovich, “Functional States of Myeloid Cells in Cancer,” Cancer Cell 41, no. 3 (2023): 490-504.

[8] J. Yu, X. Chen, S. Zhao, J. Jing, Q. Wang, and Y. Dang, “HOXC10 Promotes Metastasis in Colorectal Cancer by Recruiting Myeloid-Derived Suppressor Cells,” Journal of Cancer 13, no. 12 (2022): 3308-3317.

[9] G. Yan, H. Zhao, Q. Zhang, et al., “A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis,” Cancer Research 78, no. 19 (2018): 5586-5599.

[10] Y. Chen, Y. Xu, H. Zhao, et al., “Myeloid-Derived Suppressor Cells Deficient in Cholesterol Biosynthesis Promote Tumor Immune Evasion,” Cancer Letters 564 (2023): 216208.

[11] L. Wu, X. Liu, J. Lei, et al., “Fibrinogen-Like Protein 2 Promotes Tumor Immune Suppression by Regulating Cholesterol Metabolism in Myeloid-Derived Suppressor Cells,” Journal for ImmunoTherapy of Cancer 11, no. 12 (2023): e008081.

[12] Y. Wu, M. Yi, M. Niu, Q. Mei, and K. Wu, “Myeloid-Derived Suppressor Cells: An Emerging Target for Anticancer Immunotherapy,” Molecular Cancer 21, no. 1 (2022): 184.

[13] J. Luo, H. Yang, and B.-L. Song, “Mechanisms and Regulation of Cholesterol Homeostasis,” Nature Reviews Molecular Cell Biology 21, no. 4 (2020): 225-245.

[14] Y. Duan, K. Gong, S. Xu, F. Zhang, X. Meng, and J. Han, “Regulation of Cholesterol Homeostasis in Health and Diseases: From Mechanisms to Targeted Therapeutics,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 265.

[15] J. G. Cyster, E. V. Dang, A. Reboldi, and T. Yi, “25-Hydroxycholesterols in Innate and Adaptive Immunity,” Nature Reviews Immunology 14, no. 11 (2014): 731-743.

[16] J. Xiao, S. Wang, L. Chen, et al., “25-Hydroxycholesterol Regulates Lysosome AMP Kinase Activation and Metabolic Reprogramming to Educate Immunosuppressive Macrophages,” Immunity 57, no. 5 (2024): 1087-1104.

[17] M. K. Gleason, J. A. Ross, E. D. Warlick, et al., “CD16xCD33 Bispecific Killer Cell Engager (BiKE) Activates NK Cells Against Primary MDS and MDSC CD33+ Targets,” Blood 123, no. 19 (2014): 3016-3026.

[18] L. Zhou, K. Miao, B. Yin, et al., “Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure,” Circulation 138, no. 2 (2018): 181-197.

[19] C. Perez, C. Botta, A. Zabaleta, et al., “Immunogenomic Identification and Characterization of Granulocytic Myeloid-Derived Suppressor Cells in Multiple Myeloma,” Blood 136, no. 2 (2020): 199-209.

[20] P. Goossens, J. Rodriguez-Vita, A. Etzerodt, et al., “Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression,” Cell Metabolism 29, no. 6 (2019): 1376-1389.

[21] J. E. Talmadge and D. I. Gabrilovich, “History of Myeloid-Derived Suppressor Cells,” Nature Reviews Cancer 13, no. 10 (2013): 739-752.

[22] S. Dadsena, R. Cuevas Arenas, G. Vieira, S. Brodesser, M. N. Melo, and A. J. García-Sáez, “Lipid Unsaturation Promotes BAX and BAK Pore Activity During Apoptosis,” Nature Communications 15, no. 1 (2024): 4700.

[23] E. S. Gan, H. C. Tan, D. H. T. Le, et al., “Dengue Virus Induces PCSK9 Expression to Alter Antiviral Responses and Disease Outcomes,” Journal of Clinical Investigation 130, no. 10 (2020): 5223-5234.

[24] C. An, F. Sun, C. Liu, et al., “IQGAP1 promotes Mitochondrial Damage and Activation of the mtDNA Sensor cGAS-STING Pathway to Induce Endothelial Cell Pyroptosis Leading to Atherosclerosis,” International Immunopharmacology 123 (2023): 110795.

[25] T.-T. Chu, X. Tu, K. Yang, J. Wu, J. J. Repa, and N. Yan, “Tonic Prime-Boost of STING Signalling Mediates Niemann-Pick Disease Type C,” Nature 596, no. 7873 (2021): 570-575.

[26] Q. Wang, X. Liu, Y. Cui, et al., “The E3 Ubiquitin Ligase AMFR and INSIG1 Bridge the Activation of TBK1 Kinase by Modifying the Adaptor STING,” Immunity 41, no. 6 (2014): 919-933.

[27] F. Lin, X. Yao, C. Kong, et al., “25-Hydroxycholesterol Protecting From Cerebral Ischemia-Reperfusion Injury Through the Inhibition of STING Activity,” Aging (Albany New York) 13, no. 16 (2021): 20149-20163.

[28] D. Peng, Z. Huang, H. Yang, Y. Luo, and Z. Wu, “PPM1G Regulates Hepatic Ischemia/Reperfusion Injury Through STING-Mediated Inflammatory Pathways in Macrophages,” Immunity, Inflammation and Disease 12, no. 2 (2024): e1189.

[29] M.-G. Cho, R. J. Kumar, C.-C. Lin, et al., “MRE11 Liberates cGAS From Nucleosome Sequestration During Tumorigenesis,” Nature 625, no. 7995 (2024): 585-592.

[30] M. S. Woo, C. Mayer, L. Binkle-Ladisch, et al., “STING Orchestrates the Neuronal Inflammatory Stress Response in Multiple Sclerosis,” Cell 187, no. 15 (2024): 4043-4060.

[31] B. Zhao, F. Du, P. Xu, et al., “A Conserved PLPLRT/SD Motif of STING Mediates the Recruitment and Activation of TBK1,” Nature 569, no. 7758 (2019): 718-722.

[32] J.-F. Clément, S. Meloche, and M. J. Servant, “The IKK-Related Kinases: From Innate Immunity to Oncogenesis,” Cell Research 18, no. 9 (2008): 889-899.

[33] L. Pan, L. Yang, Z. Yi, W. Zhang, and J. Gong, “TBK1 Participates in Glutaminolysis by Mediating the Phosphorylation of RIPK3 to Promote Endotoxin Tolerance,” Molecular Immunology 147 (2022): 101-114.

[34] R. S. Herbst, G. Giaccone, F. de Marinis, et al., “Atezolizumab for First-Line Treatment of PD-L1-Selected Patients With NSCLC,” New England Journal of Medicine 383, no. 14 (2020): 1328-1339.

[35] J. Larkin, F. S. Hodi, and J. D. Wolchok, “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma,” New England Journal of Medicine 373, no. 13 (2015): 1270-1271.

[36] D. T. Le, J. N. Uram, H. Wang, et al., “PD-1 Blockade in Tumors With Mismatch-Repair Deficiency,” New England Journal of Medicine 372, no. 26 (2015): 2509-2520.

[37] S. Takei, Y. Tanaka, Y.-T. Lin, et al., “Multiomic Molecular Characterization of the Response to Combination Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer,” Journal for ImmunoTherapy of Cancer 12, no. 2 (2024): e008210.

[38] A. B. Benson, A. P. Venook, M. Adam, et al., “Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN 22, no. 2D (2024): e240029.

[39] T. André, K.-K. Shiu, T. W. Kim, et al., “Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer,” New England Journal of Medicine 383, no. 23 (2020): 2207-2218.

[40] T. André, E. Elez, H.-J. Lenz, et al., “Nivolumab Plus Ipilimumab Versus Nivolumab in Microsatellite Instability-High Metastatic Colorectal Cancer (CheckMate 8HW): A Randomised, Open-Label, Phase 3 Trial,” Lancet 405, no. 10476 (2025): 383-395.

[41] M. J. Overman, R. McDermott, J. L. Leach, et al., “Nivolumab in Patients With Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study,” Lancet Oncology 18, no. 9 (2017): 1182-1191.

[42] D. R. Almquist, D. H. Ahn, and T. S. Bekaii-Saab, “The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma,” Biodrugs 34, no. 3 (2020): 349-362.

[43] D. Zou, X. Xin, Y. Xu, H. Xu, L. Huang, and T. Xu, “Improving the Efficacy of Immunotherapy for Colorectal Cancer: Targeting Tumor Microenvironment-Associated Immunosuppressive Cells,” Heliyon 10, no. 16 (2024): e36446.

[44] P. Sharma, B. A. Siddiqui, S. Anandhan, et al., “The Next Decade of Immune Checkpoint Therapy,” Cancer Discovery 11, no. 4 (2021): 838-857.

[45] M. Angelova, P. Charoentong, H. Hackl, et al., “Characterization of the Immunophenotypes and Antigenomes of Colorectal Cancers Reveals Distinct Tumor Escape Mechanisms and Novel Targets for Immunotherapy,” Genome Biology 16, no. 1 (2015): 64.

[46] G. Zhong, C. He, S. Wang, C. Lin, and M. Li, “Research Progress on the Mechanism of Cholesterol-25-Hydroxylase in Intestinal Immunity,” Frontiers in Immunology 14 (2023): 1241262.

[47] U. Diczfalusy, K. E. Olofsson, A.-M. Carlsson, et al., “Marked Upregulation of Cholesterol 25-Hydroxylase Expression by Lipopolysaccharide,” Journal of Lipid Research 50, no. 11 (2009): 2258-2264.

[48] E. V. Dang, J. G. McDonald, D. W. Russell, and J. G. Cyster, “Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation,” Cell 171, no. 5 (2017): 1057-1071.

[49] F. A. de Freitas, D. Levy, C. O. Reichert, E. Cunha-Neto, J. Kalil, and S. P. Bydlowski, “Effects of Oxysterols on Immune Cells and Related Diseases,” Cells 11, no. 8 (2022): 1251.

[50] A. Canfrán-Duque, N. Rotllan, X. Zhang, et al., “Macrophage-Derived 25-Hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling,” Circulation 147, no. 5 (2023): 388-408.

[51] Z. Li, M. Martin, J. Zhang, et al., “Krüppel-Like Factor 4 Regulation of Cholesterol-25-Hydroxylase and Liver X Receptor Mitigates Atherosclerosis Susceptibility,” Circulation 136, no. 14 (2017): 1315-1330.

[52] C. Liu, X. V. Yang, J. Wu, et al., “Oxysterols Direct B-Cell Migration Through EBI2,” Nature 475, no. 7357 (2011): 519-523.

[53] Z. Lu, N. McBrearty, J. Chen, et al., “ATF3 and CH25H Regulate Effector Trogocytosis and Anti-Tumor Activities of Endogenous and Immunotherapeutic Cytotoxic T Lymphocytes,” Cell Metabolism 34, no. 9 (2022): 1342-1358.

[54] Z. Lu, J. Chen, P. Yu, et al., “Tumor Factors Stimulate Lysosomal Degradation of Tumor Antigens and Undermine Their Cross-Presentation in Lung Cancer,” Nature Communications 13, no. 1 (2022): 6623.

[55] Y. Wang, J. Luo, A. Alu, X. Han, Y. Wei, and X. Wei, “cGAS-STING Pathway in Cancer Biotherapy,” Molecular Cancer 19, no. 1 (2020): 136.

[56] M. Motwani, S. Pesiridis, and K. A. Fitzgerald, “DNA Sensing by the cGAS-STING Pathway in Health and Disease,” Nature Reviews Genetics 20, no. 11 (2019): 657-674.

[57] Z. Zhang and C. Zhang, “Regulation of cGAS-STING Signalling and Its Diversity of Cellular Outcomes,” Nature Reviews Immunology 25, no. 6 (2025): 425-444.

[58] K.-P. Hopfner and V. Hornung, “Molecular Mechanisms and Cellular Functions of cGAS-STING Signalling,” Nature Reviews Molecular Cell Biology 21, no. 9 (2020): 501-521.

[59] F. Luchetti, R. Crinelli, E. Cesarini, et al., “Endothelial Cells, Endoplasmic Reticulum Stress and Oxysterols,” Redox Biology 13 (2017): 581-587.

[60] N. Shibata, A. F. Carlin, N. J. Spann, et al., “25-Hydroxycholesterol Activates the Integrated Stress Response to Reprogram Transcription and Translation in Macrophages,” Journal of Biological Chemistry 288, no. 50 (2013): 35812-35823.

[61] E. Mohamed, R. A. Sierra, and J. Trillo-Tinoco, “The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors Through Inhibition of STING Signaling,” Immunity 52, no. 4 (2020): 668-682.

[62] R. A. Faulkner, Y. Yang, J. Tsien, T. Qin, and R. A. DeBose-Boyd, “Direct Binding to Sterols Accelerates Endoplasmic Reticulum-Associated Degradation of HMG CoA Reductase,” PNAS 121, no. 7 (2024): e2318822121.

[63] Y. Ji, Y. Luo, Y. Wu, et al., “SEL1L-HRD1 Endoplasmic Reticulum-Associated Degradation Controls STING-Mediated Innate Immunity by Limiting the Size of the Activable STING Pool,” Nature Cell Biology 25, no. 5 (2023): 726-739.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.